Systemic review looked at the survival of 120,000 patients with cancer who took aspirin, compared with 400,000 patients who did not, showed that following the diagnosis of some cancers the proportion of patients who were still alive was 20-30% greater in those taking the drug and reduced cancer spread.The use of low-dose aspirin as a preventive measure in heart disease, stroke and cancer is well established but evidence is now emerging that the drug may have a valuable role as an additional treatment for cancer. One of the colon cancer researchers suggested that a non-diabetic man of about 65 years who takes aspirin would have a prognosis similar to that of a man five years his junior who takes none.For a woman of similar age with colon cancer the addition of aspirin could lead to a similar prognosis of a woman four years younger. Half the studies included in the review were of patients with bowel cancer, and most of the other studies were of patients with breast or prostate cancer. There were very few studies of patients with other less common cancers, but on the whole the pooled evidence for all the cancers is suggestive of benefit from aspirin.
Earn Bitcoin
Among those who had the proportion of patients taking aspirin who had a ‘serious’ bleed was no greater than the proportion of patients not taking aspirin who had experienced a ‘spontaneous’ stomach bleed due to causes other than aspirin. In two studies a very small number of fatal stomach bleeds had occurred, but again the proportion was no greater in the patients on aspirin than in those not taking aspirin. Patients with cancer should be given the evidence now available and be helped to make their own judgement of the balance between the risks and the benefits of daily low dose.
Posted by 
